Ergothioneine: History and Discovery

Ergothioneine is unusual among antioxidants in that it has no folk tradition, no ancient healers, and no single food culture built around it — its story is almost entirely a laboratory story. It begins in 1909, when a French chemist pulled an odd, sulfur-bearing crystal out of a poisonous grain fungus and gave it a name that has stuck for more than a century. From there the molecule was structurally solved, chemically synthesized, found unexpectedly concentrated in red blood cells and semen, set aside as a biochemical curiosity for decades, and finally revived in our own time as a possible “longevity vitamin.” This article traces what the documented record actually supports: who isolated it and when, who worked out its structure, how its strange chemistry was understood, the moment a dedicated human transporter for it was discovered, and how it came to be studied for aging, the brain, and the heart. Where a date, a name, or a “first” is firmly recorded, we say so; where the record is thin or an attribution is debated, we mark it as such.

Table of Contents

  1. A Molecule Named for Ergot
  2. 1909: Tanret Isolates It from a Grain Fungus
  3. 1911: Barger and Ewins Solve the Structure
  4. 1950: Made in the Laboratory
  5. Found in Blood, Semen, and the Eye
  6. From Curiosity to Antioxidant Hypothesis
  7. 2005: A Dedicated Human Transporter
  8. The Modern Era: A “Longevity Vitamin”
  9. Research Papers and References
  10. Connections
  11. Featured Videos

A Molecule Named for Ergot

The name ergothioneine is a small history lesson in itself. It joins ergo-, from ergot — the dark, toxic fungus Claviceps purpurea that infects rye and other grains — with -thio-, the chemical prefix for sulfur, and a chemical ending. In plain terms, the word means “the sulfur compound from ergot.” The molecule was named after the organism it was first pulled out of, and that name has survived unchanged for over a hundred years even though we now know ergothioneine is made by many fungi and bacteria, not just ergot.

That origin is worth pausing on, because ergot was one of the most feared substances in pre-modern Europe. Bread baked from ergot-contaminated rye caused outbreaks of ergotism — the burning pain, gangrene, and convulsions once called “St. Anthony’s Fire.” By the late nineteenth and early twentieth centuries, ergot had also become an important source of medicinal alkaloids, which is exactly why chemists were busy taking it apart. Ergothioneine was a by-product of that work: not a poison and not the drug anyone was hunting for, but a clean, stable crystal that turned out to be far more interesting than it first appeared.

Chemically, the compound is precise enough to name exactly: ergothioneine is 2-mercaptohistidine trimethylbetaine — a sulfur-bearing, fully methylated derivative of the amino acid histidine. That single sentence took the better part of forty years and several laboratories to establish, which is the thread the next three sections follow.

Back to Table of Contents

1909: Tanret Isolates It from a Grain Fungus

The documented discovery is firm and well attributed. In 1909, the French pharmacist and chemist Charles Tanret isolated ergothioneine from the ergot fungus Claviceps purpurea and reported it to the French Academy of Sciences. His note carried the title “Sur une base nouvelle retirée du seigle ergoté: l’ergothionéine” — “On a new base obtained from ergoted rye: ergothioneine” — and appeared in the academy’s proceedings (the Comptes rendus). Tanret obtained the substance as a crystalline compound and reported an early empirical formula, C9H15N3S; later work corrected this to the modern molecular formula C9H15N3O2S, which accounts for the carboxylate group of the underlying amino acid.

Two details from that first description matter for everything that came later. First, Tanret recognized that the molecule contained sulfur — the feature that would eventually make it interesting as an antioxidant. Second, he noted that it was a remarkably stable, well-behaved crystal, not the reactive, easily spoiled material that sulfur-containing compounds often are. That stability, puzzling at the time, turns out to be the heart of the molecule’s biology, and it is why ergothioneine could be isolated, weighed, and studied with the relatively simple chemistry of 1909 in the first place.

It is fair to call this a genuine, single-author discovery with a named discoverer and a firm date — the kind of clean origin that many natural compounds lack. What Tanret did not know, and could not have known, was what the molecule was for. He had a name, a formula, and a source. The structure and the biology were left to others.

Back to Table of Contents

1911: Barger and Ewins Solve the Structure

Just two years after Tanret’s isolation, the structural puzzle was largely solved. In 1911, the British chemists George Barger and Arthur James Ewins, working in London, published “The constitution of ergothioneine: a betaine related to histidine” in the Journal of the Chemical Society, Transactions. Using the degradation and reactivity methods of classical organic chemistry — breaking the molecule into recognizable fragments and reasoning backward — they showed that ergothioneine is a betaine derivative of the amino acid histidine, carrying a sulfur (thiol/thione) group on the imidazole ring.

This was the conceptual breakthrough. Histidine was a known amino acid; a “betaine” meant the molecule’s nitrogen was fully methylated and internally charged, which explained its water solubility and stability; and the sulfur on the ring explained its redox chemistry. In modern shorthand, Barger and Ewins had established that ergothioneine is the trimethylated, 2-thiol form of histidine — the definition still used today. (Their 1911 assignment was independently corroborated by later workers, notably Shiro Akabori, before it was finally locked down by total synthesis at mid-century.) Their structural assignment connected a mysterious fungal crystal to mainstream amino-acid chemistry and made it possible, in principle, to build the molecule from scratch.

The link to histidine is more than a chemical footnote. It is the reason ergothioneine’s biosynthesis (in the fungi and bacteria that make it) starts from histidine, and the reason the body’s histidine biochemistry and ergothioneine are quietly related. Barger and Ewins gave the molecule its family tree.

Back to Table of Contents

1950: Made in the Laboratory

A proposed structure in chemistry is only fully proven when someone builds the molecule from simple ingredients and shows the synthetic product is identical to the natural one. For ergothioneine, that confirmation came at mid-century. In 1950, the British biochemists H. Heath, A. Lawson, and C. Rimington reported the chemical synthesis of ergothioneine in the journal Nature, with a fuller account following in the Journal of the Chemical Society in 1951. Their synthetic ergothioneine matched the natural compound, confirming the Barger–Ewins structure beyond reasonable doubt.

The synthesis closed a loop that had been open for four decades: isolation in 1909, a structure in 1911, and definitive structural proof by total synthesis in 1950. Just as importantly, having a synthetic route meant researchers were no longer limited to whatever they could squeeze out of fungus. Pure, made-to-order ergothioneine could now be produced for experiments — a practical prerequisite for studying what the molecule actually does in living tissue.

It is worth being precise about what “synthesis” means here. Heath, Lawson, and Rimington did not invent ergothioneine — nature had been making it in fungi and bacteria for hundreds of millions of years. What they achieved was the human ability to construct the exact molecule deliberately, which is both a proof of structure and the foundation of every purified ergothioneine product, including the supplements sold today (most of which are now made by microbial fermentation rather than this early chemical route).

Back to Table of Contents

Found in Blood, Semen, and the Eye

If ergothioneine were merely a fungal oddity, it would have stayed in the chemistry textbooks. What kept biologists interested through the middle of the twentieth century was a surprising fact: the molecule turned up in animal tissues — sometimes in striking amounts — even though animals cannot make it. As analytical methods improved, researchers documented that ergothioneine is concentrated in mammalian red blood cells (erythrocytes), in the lens of the eye, in the skin, and, most dramatically, in semen and seminal fluid.

The reproductive findings were especially memorable. In several mammals — the boar, the stallion, the donkey, and the hedgehog among them — ergothioneine occurs at high concentrations in seminal fluid. Mid-twentieth-century studies of boar seminal plasma (a convenient, abundant source) reported ergothioneine levels many times higher than in blood, and used that secretion to purify and crystallize the compound. These observations established two things that frame all later work: ergothioneine is a normal, widespread constituent of the vertebrate body, and the body does not scatter it at random — it piles it up in particular tissues.

That selective accumulation posed an obvious puzzle. A molecule the body cannot synthesize, must obtain from food, and then deliberately concentrates in specific high-stress tissues looks like something the body values. For decades, though, no one could say why, or how it got where it was going. The “how” would not be answered until 2005; the “why” is still being worked out. In the meantime, the unexplained tissue distribution was the strongest hint that ergothioneine was more than an accident of diet.

Back to Table of Contents

From Curiosity to Antioxidant Hypothesis

For much of the twentieth century ergothioneine sat in an awkward middle ground: clearly present in the body, clearly accumulated on purpose, but with no agreed-upon function. It was studied in bursts and then set aside — a recurring pattern that several modern reviewers describe as the molecule being repeatedly “rediscovered.” Its very stability worked against it: a thiol that refuses to react readily did not fit neatly into the metabolic schemes of the day.

The turning point in interpretation came toward the end of the century, when the molecule’s chemistry was reconsidered through the lens of oxidative-stress biology. A widely cited 1990 contribution by P. E. Hartman, “Ergothioneine as antioxidant” in Methods in Enzymology, helped crystallize the idea that ergothioneine’s distinctive redox behavior — its ability to intercept hydrogen peroxide, certain radicals, and reactive electrophiles without itself becoming a damaging pro-oxidant — could make it a genuine physiological antioxidant. This reframing turned a long-puzzling stability into the molecule’s defining virtue: ergothioneine could sit quietly in a cell as a stable reserve and act only when oxidative trouble arrived.

The antioxidant hypothesis tied the loose threads together. It explained why the body would concentrate ergothioneine in red blood cells, the lens, the skin, and reproductive fluids — all tissues under heavy oxidative or radical load. It connected ergothioneine to the broader family of protective molecules the body relies on, alongside glutathione and others. And it set the research agenda for the modern era: if this diet-derived compound is a protective antioxidant the body cannot make, how does it get into the cells that need it, and what happens when there is too little of it?

Back to Table of Contents

2005: A Dedicated Human Transporter

The single most important modern milestone in ergothioneine’s story arrived in 2005. A team led by Dirk Gründemann reported in the Proceedings of the National Academy of Sciences that a membrane protein previously catalogued as a generic “organic cation transporter” — OCTN1, the product of the gene SLC22A4 — in fact transports ergothioneine with high efficiency and selectivity. They used a metabolite-screening approach to ask what the transporter’s true preferred cargo was, and the answer came back overwhelmingly: ergothioneine.

This was the discovery that flipped ergothioneine from “curious dietary molecule” to “something the body is built to capture.” A dedicated, high-affinity transporter is exactly what you would expect for a substance the body cannot make but cannot do without — the same logic that applies to vitamins. OCTN1 is now so closely identified with this one job that it is frequently called simply the ergothioneine transporter (ETT). Its presence in blood cells, eye, liver, kidney, gut, lung, skin, and brain neatly matched the tissue distribution that had puzzled earlier researchers: the body delivers ergothioneine to precisely the places under the greatest oxidative stress.

The transporter discovery did something a chemical structure never could — it provided a strong physiological argument that ergothioneine matters. Evolution does not maintain a selective uptake-and-retention system for a molecule with no role. From 2005 onward, the question was no longer whether ergothioneine is biologically important, but how important, and for what.

Back to Table of Contents

The Modern Era: A “Longevity Vitamin”

The years since the transporter discovery have been the busiest in ergothioneine’s long history. Two further strands deserve mention. First, the molecule’s biosynthesis was finally worked out in the organisms that make it: in 2010, Florian Seebeck reconstituted the bacterial ergothioneine pathway from Mycobacterium smegmatis in vitro (identifying the egt genes), and the parallel fungal pathway (the Egt1/Egt2 enzymes) was described soon afterward. Understanding these enzymes is what made it practical to manufacture ergothioneine by fermentation — the basis of today’s commercial supply.

Second, and most influentially for the public, ergothioneine was folded into a broad theory of healthy aging. In 2018, the biochemist Bruce Ames proposed in the Proceedings of the National Academy of Sciences the concept of “longevity vitamins”: nutrients that are not required to prevent an immediate deficiency disease, but that the body needs for long-term health and lifespan, and which it quietly sacrifices when supplies run short. Ames named ergothioneine explicitly as a candidate. The label caught on quickly, reinforced by large human cohort studies in which low blood ergothioneine was associated with higher risk of cardiovascular disease, cognitive decline, frailty, and death, and by the observation that mushroom-rich diets — the main dietary source — track with healthier aging.

It is important to be honest about where this leaves us. Ergothioneine is not an officially recognized vitamin; there is no recommended daily allowance, and the “longevity vitamin” framing is a well-argued hypothesis, not a settled classification. Long-term randomized trials proving that taking ergothioneine extends human healthspan have not yet been completed. What the historical record does show is a remarkable arc: a sulfur compound scraped from a poisonous fungus in 1909, structurally solved in 1911, synthesized in 1950, found hoarded in our blood and tissues, given a dedicated transporter in 2005, and now studied as a possible key to aging well. The fuller account of its mechanisms, food sources, dosing, and the disease research is told on the main Ergothioneine page; this history is concerned with how we came to know about it at all.

Back to Table of Contents

Research Papers and References

The list below combines the landmark historical papers in ergothioneine research with key modern reviews. Charles Tanret’s original 1909 note in the Comptes rendus of the French Academy of Sciences is named here as a historical primary source. Author names, titles, and journals are given as plain text; only the stable DOI, PMID, or article URL is hyperlinked, and each opens in a new tab. Every linked citation has been checked to resolve to the paper described.

  1. Tanret C. Sur une base nouvelle retirée du seigle ergoté, l’ergothionéine. Comptes rendus hebdomadaires des séances de l’Académie des sciences. 1909;149:222–224. — original isolation of ergothioneine (historical primary source; no stable DOI).
  2. Barger G, Ewins AJ. CCLVII. The constitution of ergothioneine: a betaine related to histidine. Journal of the Chemical Society, Transactions. 1911;99:2336–2341. — doi:10.1039/CT9119902336
  3. Heath H, Lawson A, Rimington C. Synthesis of ergothioneine. Nature. 1950;166(4214):106. — doi:10.1038/166106a0
  4. Hartman PE. Ergothioneine as antioxidant. Methods in Enzymology. 1990;186:310–318. — PMID: 2172707
  5. Gründemann D, Harlfinger S, Golz S, et al. Discovery of the ergothioneine transporter. Proceedings of the National Academy of Sciences USA. 2005;102(14):5256–5261. — doi:10.1073/pnas.0408624102
  6. Seebeck FP. In vitro reconstitution of mycobacterial ergothioneine biosynthesis. Journal of the American Chemical Society. 2010;132(19):6632–6633. — doi:10.1021/ja101721e
  7. Ames BN. Prolonging healthy aging: longevity vitamins and proteins. Proceedings of the National Academy of Sciences USA. 2018;115(43):10836–10844. — doi:10.1073/pnas.1809045115
  8. Borodina I, Kenny LC, McCarthy CM, et al. The biology of ergothioneine, an antioxidant nutraceutical. Nutrition Research Reviews. 2020;33(2):190–217. — doi:10.1017/S0954422419000301
  9. Beelman RB, Kalaras MD, Phillips AT, Richie JP Jr. Is ergothioneine a “longevity vitamin” limited in the American diet? Journal of Nutritional Science. 2020;9:e52. — doi:10.1017/jns.2020.44
  10. Ergothioneine — history and discovery — PubMed: ergothioneine history and discovery
  11. Ergothioneine — transporter and physiological function — PubMed: ergothioneine transporter and physiology

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents